Methylation of somatostatin receptor 2 gene in neuroendocrine tumours as a predictor of tumour response to peptide receptor radionuclide therapy

Somatostatin receptors are a fundamental target for treating neuroendocrine tumours (NETs) with ‘cold’ or ‘hot’ somatostatin analogues. Metastatic NETs progressing after medical therapy can receive peptide receptor radionuclide therapy (PRRT) on the precondition that patients exhibit